Median survival reported in studies evaluating cytoreductive surgery with hyperthermic intraperitoneal and/or early postoperative chemotherapy for mesothelioma
| Study | Year | Treatment | Median survival, mo |
|---|---|---|---|
| Sebbag et al. (39) | 2000 | CRS, HIPEC, EPIC (cisplatin and doxorubicin) | 31.0 |
| Loggie et al. (40) | 2001 | CRS, HIPEC (mitomycin) | 34.2 |
| Deraco et al. (41) | 2003 | CRS, HIPEC (cisplatin and mitomycin OR cisplatin and doxorubicin) | 28.0 |
| Feldman et al. (42) | 2003 | CRS, HIPEC (cisplatin and doxorubicin) EPIC (5FU and paclitaxel) | 28.3 |
| Brigand et al. (43) | 2006 | CRS, HIPEC (cisplatin and mitomycin) | 35.6 |
| Yan et al. (38) | 2007 | CRS, HIPEC Systematic review of published and unpublished data from 7 observational studies | 34–92 |
CRS = cytoreductive surgery; EPIC = early postoperative chemotherapy; HIPEC = hyperthermic intraperitoneal chemotherapy.